GlucoTrack Inc (GCTK) Stock Analysis

Verdict: AVOID

Severe toxic dilution and under 1 month cash runway overwhelm any biopharma asset pipeline potential post-Lokahi merger.

Investment score: 7/100

Analysis as of

Is GlucoTrack Inc stock worth reviewing? The TradeMates thesis

The TradeMates model strongly advises avoiding GCTK due to imminent cash exhaustion, negative stockholders' equity (-$1.74M), and continuous toxic debt dilution.

7-factor investment score

GlucoTrack Inc opportunities and risks

What speaks for GCTK

What speaks against GCTK

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
GCTKn/a0.0xn/a0.0%0.0%-1269.1%
BJDXn/a0.0x1.3x0.0%0.0%-1076.5%
RMSLn/a91.4xn/a-0.8%-11339590839.7%-20646217.5%
UAHC180.0x0.0xn/a0.0%0.0%40.8%
XAIRn/a0.2xn/a4.2%-435.7%-1443.1%
NXLn/a5.8xn/a-148.4%-4139.4%-495.1%
Peer mediann/a0.2xn/a0.0%-435.7%-1076.5%

Frequently asked questions about GlucoTrack Inc (GCTK)

Is GCTK stock a good investment?

The TradeMates model rates GlucoTrack Inc as AVOID with an investment score of 7/100. The TradeMates model strongly advises avoiding GCTK due to imminent cash exhaustion, negative stockholders' equity (-$1.74M), and continuous toxic debt dilution. This is algorithmic model output, not personal investment advice.

Is GCTK stock a buy?

The TradeMates model verdict for GCTK is AVOID with an investment score of 7/100. Treat this as a model signal to review, not a personal buy recommendation.